Astra expands diabetes alliance with Bristol-Myers Squibb

AstraZeneca (AZN) has said that it will benefit from Bristol-Myers Squibb's (BMS's) acquisition of Amylin Pharmaceuticals as it strengthens the leadership position of its diabetes alliance with BMS in a 'growing area of high unmet medical need'.

AstraZeneca (AZN) has said that it will benefit from Bristol-Myers Squibb's (BMS's) acquisition of Amylin Pharmaceuticals as it strengthens the leadership position of its diabetes alliance with BMS in a 'growing area of high unmet medical need'.

US biopharmaceutical giant BMS has announced on Monday that it will buy Amylin for around $5.3bn, a deal that has been unanimously recommended.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.